<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906292</url>
  </required_header>
  <id_info>
    <org_study_id>Fascination</org_study_id>
    <secondary_id>2018-002256-33</secondary_id>
    <nct_id>NCT03906292</nct_id>
  </id_info>
  <brief_title>Frontline Asciminib Combination in Chronic Phase CML</brief_title>
  <acronym>CMLXI</acronym>
  <official_title>Frontline Asciminib Combination in Chronic Phase CML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult male and female patients with newly diagnosed Philadelphia chromosome positive (Ph+)&#xD;
      and/or BCR-ABL1 positive CML can be included in the study until 3 months after diagnosis. A&#xD;
      &lt;4 week pretreatment with hydroxyurea is permitted. Patients treated for &lt;6 weeks with&#xD;
      nilotinib 300 mg BID, imatinib 400 mg QD, dasatinib 100 mg QD or without any therapy are&#xD;
      eligible for recruitment and will be allocated to the respective cohort. All patients must&#xD;
      provide written informed consent to be enrolled in the trial. Cohorts were designed to allow&#xD;
      assessment of QD and BID asciminib based combinations to optimize quality of life and&#xD;
      compliance. Patients will not be randomized. In general, cohorts will be filled&#xD;
      consecutively. Asciminib therapy will be commenced 12 weeks after start of nilotinib,&#xD;
      imatinib or dasatinib and after recovery of hematopoiesis or in case of no therapy so far 6&#xD;
      weeks after diagnosis as first line treatment. Referred patients already treated with&#xD;
      imatinib, nilotinib or dasatinib will remain on the initial drug and will be allocated to the&#xD;
      respective cohort.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the dramatic progress made over the past decade with TKIs in the treatment of CML,&#xD;
      allogeneic stem cell transplant remains the only proven curative therapy. To achieve cure or&#xD;
      benefit from treatment-free remissions with pharmacologically-based therapies, it is&#xD;
      estimated that patients will likely need to achieve a sustained reduction in tumor burden&#xD;
      corresponding to a deep molecular response of at least 4 logs (MR4). Currently, only 30.8% of&#xD;
      patients achieve a deep molecular response after 12 months of treatment with single agent&#xD;
      nilotinib.&#xD;
&#xD;
      The development of the novel and potent BCR-ABL1 allosteric inhibitor, asciminib, presents an&#xD;
      opportunity to assess the effect of a different mechanism of inhibition of BCR-ABL1 in the&#xD;
      first-line treatment of CML to enhance speed of response and to increase the patient&#xD;
      population benefitting from deep molecular response. Dosing a combination of asciminib with&#xD;
      an ATP-site inhibitor also has the potential to prevent the emergence of resistance due to&#xD;
      point mutations being acquired in one of the binding sites.&#xD;
&#xD;
      The safety, tolerability and pharmacokinetic profile of asciminib as a single agent and in&#xD;
      combination with either nilotinib or imatinib or dasatinib was assessed in a phase-I study.&#xD;
      At the doses chosen here, all three combination treatments were well tolerated.&#xD;
&#xD;
      Since in all patient cohorts the standard of care therapy will remain the backbone of initial&#xD;
      therapy, there is no reason to expect an efficacy problem with the combination therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2019</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>5 parallel cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>deep molecular response (Rate of MR4)</measure>
    <time_frame>at month 12 after Start of Standard-Therapy</time_frame>
    <description>Achievement of deep molecular response (MR4) throught standardized testing of BCR-ABL-transcript Levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>deep molecular Response (Rate of MR4.5)</measure>
    <time_frame>at month 36 after Start of Standard-Therapy</time_frame>
    <description>Achievement of deep molecular response (MR4.5) throught standardized testing of BCR-ABL-transcript Levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>molecular response (MMR and MR4.5)</measure>
    <time_frame>at and by 6, 12, 18, 24, 36 and 60 months after Start of Therapy</time_frame>
    <description>Achievement of deep molecular response throught standardized testing of BCR-ABL-transcript levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>at and by baseline, 3, 6, 12, 15, 18, 21, 24, 36 and 60 months after Start of Therapy</time_frame>
    <description>Incidence of adverse events grade 1-5 and 3-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>at month 60 after Start of Therapy</time_frame>
    <description>Progression free survival at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at month 60 after Start of Therapy</time_frame>
    <description>Overall survival at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of MR4.5 during Asciminib-monotherapy</measure>
    <time_frame>at month 36 and 60 after Start of Therapy</time_frame>
    <description>Achievement of deep molecular response (MR4.5) throught standardized testing of BCR-ABL-transcript Levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement and durability of treatment-free remission</measure>
    <time_frame>months 37 and 60 after Start of Therapy</time_frame>
    <description>Achievement of deep molecular response (MR4) throught standardized testing of BCR-ABL-transcript Levels</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Asciminib 60mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy of Imatinib 400 mg QD and asciminib 60 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asciminb 20 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy of Nilotinib 300 mg BID and asciminib 20 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asciminib 40 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy of Nilotinib 300 mg BID and asciminib 40 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asciminib 80 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy of Dasatinib 100 mg QD and asciminib 80 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asciminib 80 mg QD monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asciminib 80 mg QD as a single agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>Imatinib 400 mg QD and asciminib 60 mg QD</description>
    <arm_group_label>Asciminib 60mg QD</arm_group_label>
    <other_name>Imatinib 400 mg QD and asciminib 60 mg QD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib 300 mg</intervention_name>
    <description>Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD</description>
    <arm_group_label>Asciminb 20 mg BID</arm_group_label>
    <arm_group_label>Asciminib 40 mg QD</arm_group_label>
    <other_name>Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Dasatinib 100 mg QD and asciminib 80 mg QD</description>
    <arm_group_label>Asciminib 80 mg QD</arm_group_label>
    <other_name>Dasatinib 100 mg QD and asciminib 80 mg QD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asciminib</intervention_name>
    <description>Asciminib 80 mg QD Monotherapy</description>
    <arm_group_label>Asciminb 20 mg BID</arm_group_label>
    <arm_group_label>Asciminib 40 mg QD</arm_group_label>
    <arm_group_label>Asciminib 60mg QD</arm_group_label>
    <arm_group_label>Asciminib 80 mg QD</arm_group_label>
    <arm_group_label>Asciminib 80 mg QD monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients with diagnosis of CP-CML with cytogenetic confirmation of the&#xD;
             Ph+ chromosome [t(9;22)(q34;q11)].&#xD;
&#xD;
          -  Ph-negative cases or patients with variant translocations who are BCR-ABL1 positive in&#xD;
             multiplex PCR 35 will be also considered eligible.&#xD;
&#xD;
          -  ECOG performance status of ≤2.&#xD;
&#xD;
          -  Age ≥ 18 years old (no upper age limit is given)&#xD;
&#xD;
          -  Serum levels of potassium, magnesium, total calcium within the normal limits (≥LLN&#xD;
             [lower limit of normal] and ≤ULN [upper limit of normal]). Correction of electrolytes&#xD;
             levels with supplements to fulfil enrolment criteria is allowed.&#xD;
&#xD;
          -  AST and ALT ≤2.5 x ULN or 5.0 x ULN if considered due to leukemia&#xD;
&#xD;
          -  Alkaline phosphatase ≤2.5 x ULN unless considered due to leukemia&#xD;
&#xD;
          -  Total bilirubin ≤1.5 x ULN, except known Gilbert disease&#xD;
&#xD;
          -  Serum creatinine ≤2 x ULN&#xD;
&#xD;
          -  Written informed consent prior to any study procedures being performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allogeneic stem cell transplantation&#xD;
&#xD;
          -  Known impaired cardiac function, including any of the following:&#xD;
&#xD;
               -  Congenital long QT syndrome&#xD;
&#xD;
               -  History of or presence of clinically significant ventricular or atrial&#xD;
                  tachyarrhythmia&#xD;
&#xD;
               -  QTc &gt;450 msec on screening ECG&#xD;
&#xD;
               -  Myocardial infarction within 12 months prior to starting therapy&#xD;
&#xD;
          -  Other clinical significant heart disease (e.g. unstable angina, congestive heart&#xD;
             failure)&#xD;
&#xD;
          -  Acute or chronic viral hepatitis with moderate or severe hepatic impairment&#xD;
             (Child-Pugh scores &gt;6), even if controlled&#xD;
&#xD;
          -  Other concurrent uncontrolled medical conditions (e.g., active or uncontrolled&#xD;
             infections, acute or chronic liver and renal disease) that could cause unacceptable&#xD;
             safety risks or compromise compliance with the protocol&#xD;
&#xD;
          -  Impaired gastrointestinal function or disease that may alter the absorption of study&#xD;
             drug (e.g., ulcerative disease, uncontrolled nausea, vomiting and diarrhea,&#xD;
             malabsorption syndrome, small bowel resection or gastric by-pass surgery)&#xD;
&#xD;
          -  Concomitant medications known to be strong inducers or inhibitors of the CYP450&#xD;
             isoenzyme CYP3A4&#xD;
&#xD;
          -  Patients who have undergone major surgery ≤2 weeks prior to starting study drug or who&#xD;
             have not recovered from side effects of such therapy&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding or women of reproductive potential not&#xD;
             employing an effective method of birth control. Women of childbearing potential must&#xD;
             have a negative serum pregnancy test within 14 days of study start. Post-menopausal&#xD;
             women must be amenorrheic for at least 12 months in order to be considered of&#xD;
             non-childbearing potential. Male and female patients must agree to employ an effective&#xD;
             method of birth control throughout the study and for up to 2 weeks following&#xD;
             discontinuation of study drug&#xD;
&#xD;
          -  Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not&#xD;
             mandatory)&#xD;
&#xD;
          -  Known serious hypersensitivity reactions to asciminib, imatinib, nilotinib or&#xD;
             dasatinib&#xD;
&#xD;
          -  Patients with a history of another primary malignancy that is currently clinically&#xD;
             significant or currently requires active intervention&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Ernst, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Jena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Ernst, Prof. Dr.</last_name>
    <phone>+49 3641</phone>
    <phone_ext>9396670</phone_ext>
    <email>fascination@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Fabisch, Dr.</last_name>
    <phone>+49 3641</phone>
    <phone_ext>9396670</phone_ext>
    <email>fascination@med.uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen Medizinische Klinik IV</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Crysandt, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Netzwerk für Gesundheit GmbH Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maike de Wit, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Universitätsmeditin Berlin, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp le Coutre, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lino Teichmann, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Bormann, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Hänel, PD Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GOKOS GmbH</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Illmer, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franziska Taube, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Krause, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.-Antonius-Hospital Eschweiler</name>
      <address>
        <city>Eschweiler</city>
        <zip>52249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Staib, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Göthert, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabian Lang, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelius Waller, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Ernst, PD Dr.</last_name>
      <phone>+49 3641</phone>
      <phone_ext>9324201</phone_ext>
      <email>thomas.ernst@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg-Nikolaus Franke, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Müller/ Kröning/ Jentsch-Ullrich/ Tietze/ Krogel</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Jentsch-Ullrich, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes- Gutenberg Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Radsak, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68169</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Saußele, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Burchert, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Herhaus, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brüderkrankenhaus St. Josef Paderborn</name>
      <address>
        <city>Paderborn</city>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Gaska, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brüder Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Schenk, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Stegelmann, PD Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 14, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>Thomas Ernst, PD Dr. med.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

